Analyst Moves: ABBV, RRC, HRL

0 views
  • About
  • Add to
This morning, BMO Capital increased its EPS estimates on shares of AbbVie (ABBV) through 2014 as the company's pipeline of new products continues to advance. In the report, BMO raised its price target to $48 while maintaining its market perform rating.

0 comments